Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Terminated

2(33%)

Phase Distribution

Ph phase_2

33%

Ph phase_1

50%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 3Large-scale testing

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(3)

Detailed Status

Completed3

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (50.0%)

Phase 22 (33.3%)

Phase 31 (16.7%)

Trials by Status

withdrawn117%

completed350%

terminated233%

Recent Activity

0 active trials

Showing 5 of 6

withdrawnphase_2

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

NCT00308204

completedphase_1

Efalizumab for Moderate to Severe Atopic Dermatitis

NCT00226057

completedphase_1

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

NCT00368654

terminatedphase_1

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204

completedphase_3

CLEAR Study: Clinical Experience Acquired With Raptiva Study

NCT00256139

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT00308204Phase 2

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

Withdrawn

NCT00226057Phase 1

Efalizumab for Moderate to Severe Atopic Dermatitis

Completed

NCT00368654Phase 1

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

Completed

NCT00672204Phase 1

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Terminated

NCT00256139Phase 3

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Completed

NCT00344448Phase 2

Pilot Study of Raptiva to Treat Sjogren's Syndrome

Terminated

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6